Reading EW? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track EW free→EW
Edwards LifesciencesNYSEHealth CareMedical DevicesSnapshot 2026-06-12
Intact
$85.11-0.76%
Close 2026-06-12 · 1-day change
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
The bottom line
Recent financial performance is strong. Earnings quality and management's track record are neutral. Risk is moderate, and the sector backdrop is a headwind. Compared with sector peers, EW is above typical. Peer multiples imply a price about 41% below where it trades (it looks expensive on this basis); the read is expensive, growth-justified. This assessment is provisional.
as of 2026-06-12
Quick facts
- Exchange
- NYSE
- Sector
- Health Care
- Industry
- Medical Devices
- Market cap
- $50.41B
- Employees
- —
- IPO date
- 2000-05-15
- Next earnings
- 2026-07-23
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 8 valuation methods, at three horizons. Current price $85.11. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
12-month· primaryfull
$64.39consensus
Range $38.39 – $73.65
vs price: +32% above
Method agreement — · 8 methods
No-growth: today's peer multiple on trailing earnings. The headline read.
3-yearfair
$101.37consensus
Range $58.34 – $125.99
vs price: -16% below
Method agreement — · 6 methods
Embeds projected growth. Leans optimistic by design. Upside context.
5-yearinexpensive
How much to trust our fair value
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
Durable premiumlow confidence
At $85 the market pays 32× p/e — above the 23× p/e peer median but in line with its own 32× history. That premium reflects a durable franchise our peer-anchored $64 fair value understates; treat the 'expensive vs peers' read with low confidence. Analysts: $85–$110. Not investment advice.
Multiple (P/E)
31.5x
peer 23.3x · own history 32.0x
Premium
1.4x peer
1.0x its own history
Growth the price needs
32%
our forecast 17%
Our fair value
$64.39
range $37.78 – $73.65
Analyst range(a guide on our number, not a target)Our number is below the analyst range
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
fullexpensive — growth-justified12-month view
What's priced inStretched
The market is pricing in roughly 32% near-term growth, ahead of our forecast of about 17%. This describes what's priced in, not a forecast of the move.
Low fragilityrisk posture, not a price call
Only weak execution quality, a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Historical context
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
How strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
strongOperating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
90th pctl · Health Care
Earnings quality
neutralOver the trailing year it converted 1.24x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 50% for the rest of the cohort, n=2269).
38th pctl · Health Care
Macro sensitivity
Most sensitive to the broad stock market.
- the broad stock market: This stock moves with the broad market (high beta).
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
Management & capital allocation
neutralEarnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Earnings setup · pre-print positioning
forward-looking
Strongly bullish23 analysts, 72% Buyfor period ending 2026-06-30
Why this setup
Consensus revisions
EPS estimate $0.74 → $0.74 (+0.1% / 30d). 1 raised, 0 cut, 23 covering analysts.
Rating actions
0 upgrades, 0 downgrades / 30d, 1 maintained. 72% of analysts rate Buy.
Market and fundamentals agree. Analysts are positioned bullishly on a fundamentally strong name.
Sector context
Intermediate · WeeklySector phase: health care is in maturing, with decelerating (~0.5 years in phase).
Sector regime (90d momentum): headwind.Management scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Overall: strong
- Capital allocation
- strong
- Earnings discipline
- strong
- Margin discipline
- strong
- Balance sheet
- strong
- Guidance credibility
- weak
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$108.
How much price usually moves either way.
On a bad day, this stock has moved -$222.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $1,273.
Deepest peak-to-trough drop in the last year.
moderateas of 2026-06-12
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- label change · valuation_labelsmall change
Valuation label changed from 'expensive' to 'full'.
No material changes since the prior snapshot.
as of 2026-06-12
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Intermediate · Weekly
- UpsideHigh confidenceQuartersactive 7d
Watch for TMTT sales growth exceeding 35% in 2026
Why it matters: Strong TMTT sales growth will confirm the success of new therapies like EVOQUE and PASCAL. This is key for overall revenue growth.
What confirms / what disproves
Confirms:TMTT sales growth exceeds 35% year over year in 2026.
Disproves:TMTT sales growth is below 35% year over year in 2026.
Earnings call
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for EW yet.
This sector is also watching
- Watch for Health Care revenue growth dropping below 8% YoY
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If sector bellwethers like ABT, SYK, and MDT keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting EW and other Healthcare names. Worth watching these names for early signals.
- If the Fed starts cutting rates from the current 3.62%, that would be a tailwind for EW and other Healthcare names, since rate-sensitive parts of the market tend to rally when the Fed eases.
- If EW beats again next quarter like it did this past one (a beat of +7% on the 2026-03-31 print), the momentum tends to extend, with Street estimates ratcheting up and the stock typically following.
Downside triggers
- If EW reverses and cuts guidance after recently raising (RAISED as of 2026-04-23), that's the worst kind of move: a credibility hit on top of the lower number. Stocks usually get punished disproportionately for this.
- If sector bellwethers like ABT, SYK, and MDT start missing or guiding lower, the Healthcare tailwind helping EW and other Healthcare names could fade. Watch these names for early warning.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-041mo agoItem 5.02
Chief Financial Officer — Theodora Mistras: Edwards Lifesciences Corporation hired Theodora Mistras as the new Chief Financial Officer.
Executive changeneutral
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
+9.4 vs last weeklatest as of 2026-06-13
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.